May 2022 | Targeted Therapies in Oncology

June 02, 2022

During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed prognostic models for myelofibrosis and the use of JAK inhibitors as therapy.

May 25, 2022

May 24, 2022

Describing the role of VISTA, an immunoregulatory molecule involved in maintaining T-cell and myeloid quiescence, as a promising target in cancer immunotherapy.

May 23, 2022

With expanding knowledge of the molecular characteristics of uterine sarcomas, investigators are working to develop treatments specific to each subtype.

May 22, 2022

At the upcoming 23rd Annual International Lung Cancer Congress®, Solange Peters, MD, PhD will be giving two presentation around relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged non–small cell lung cancer.

May 21, 2022

Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.

May 21, 2022

With results offering promising efficacy data and a manageable safety profile, unecritinib can be regarded as a new first-line treatment option.

May 18, 2022

An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,

May 18, 2022

Thomas Flaig, MD, addressed new and emerging systemic therapies for bladder cancer during the National Comprehensive Cancer Network 2022 Annual Conference.

May 16, 2022

Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.

May 16, 2022

In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.

May 16, 2022

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

May 16, 2022

New and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.

May 16, 2022

There is a role for these overlapping entities—guidelines and pathways—and each permits flexibility for the oncologist for available treatment options in the level and quality of data.